Nexell Therapeutics Inc. said Tuesday it has received regulatory approval to market its Isolex system, which is used to isolate stem cells and remove tumor cells as part of aggressive treatment of cancer. Irvine-based Nexell said the product will be launched over the next several months.
The company said stem-cell transplantation is performed after high-dose chemotherapy in an effort to restore blood and immune cell production capacity.
Nexell said stem cell transplantation is an improvement over conventional transplant techniques, which use blood or marrow and can reinsert cancerous cells into the patient.
The Isolex systems are currently marketed in the European Union and Canada and are available for use in Hungary, Israel, New Zealand, Poland and Slovenia.
The company is seeking approval to market the systems in Australia, Japan and several Eastern European and Mediterranean cities.
The company’s stock was unchanged Tuesday at $2.19 a share.